Heron Therapeutics, Inc.

HRTX Healthcare Biotechnology

Heron Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $154.9 million, up 7.36% from fiscal 2024. In the quarter to June 2026, revenue grew 1.25%, EPS fell 93.6%, free cash flow grew 78.8% and total debt fell 18.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

0.36 0.02 −5.26%
Market cap
$71.5M
P/E
0.0×
Fwd P/E
−6.6×
Dividend yield
—
F-score
4/9
Altman Z
−8.84
Beneish M
−2.40
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
0.54 1.01 1.40 1.38
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(36.98) (98.52) (23.60) 161.26
P/B ratio
13.97 18.76 16.32 30.56
Price to Tangible BV
13.97 18.76 16.32 30.56
EV/Sales
1.20 1.65 2.01 1.93
EV/EBITDA
0.00 0.00 0.00 78.04
EV/Operating CF
(15.67) (12.27) (11.26) (9.90)
EV/FCF
(15.04) (11.95) (11.17) (9.63)
Quick Ratio
1.44 1.42 1.42 1.52
Current Ratio
2.49 2.53 2.48 2.56
Net Debt/EBITDA
(65.95) (23.28) 136.24 (24.67)
Debt/Assets
56.55% 57.52% 54.96% 56.10%
Debt/Equity
20.65 15.50 9.81 9.38
Asset Turnover
0.62 0.63 0.63 0.66
Operating CF/Net income
0.40 0.19 3.11 (0.08)
Capex/Depreciation
(0.26) (0.65) 0.02 0.04
Research and Development Expense of Revenue
7.17% 6.87% 9.23% 9.08%
Selling, General and Administrative Expense of Revenue
67.53% 76.21% 63.28% 70.45%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
8.44% 8.57% 5.37% 7.46%
Graham Net Nets
(0.19) (0.05) (0.02) (0.02)
Graham Number
0.00 0.00 0.00 0.00
Earnings Yield
(44.19%) (21.94%) (8.88%) (5.99%)
Free Cash Flow Yield
(14.77%) (13.71%) (12.83%) (14.46%)
Revenue per Share
0.20 0.18 0.24 0.22
Operating CF per Share
(0.01) (0.01) (0.06) 0.01
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.01) (0.01) (0.05) 0.01
Cash per Share
0.22 0.24 0.28 0.33
Shareholders Equity per Share
0.04 0.05 0.09 0.09
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
0.04 0.05 0.09 0.09
Free Cash Flow
(2.35) (1.93) (9.17) 1.36
Working Capital
137.70 138.47 141.97 139.69
Capital Expenditures
(0.14) (0.39) 0.02 0.03
Net Current Asset Value
(15.51) (8.09) (3.48) (4.66)
EV/EBIT
0.00 0.00 0.00 187.11
Capex to Sales
0.00 0.01 0.00 0.00
Price to Operating Income
0.00 0.00 0.00 134.40
Other line items
Average Receivables
84.75 81.21 84.23 74.04
Average Payables
11.84 10.65 10.35 11.10
Average Inventory
81.78 74.74 72.95 57.99
Average Assets
242.18 240.98 244.51 234.86
Average Common Equity
(10.70) (10.18) (10.18) (16.49)

Fold the line items

Columns are period end dates